Eagle Asset Management Inc. decreased its position in SAGE Therapeutics Inc (NASDAQ:SAGE) by 0.6% during the 1st quarter, HoldingsChannel reports. The fund owned 615,213 shares of the biopharmaceutical company’s stock after selling 3,815 shares during the quarter. Eagle Asset Management Inc.’s holdings in SAGE Therapeutics were worth $99,092,000 as of its most recent SEC filing.
A number of other large investors have also recently modified their holdings of the stock. Bamco Inc. NY raised its holdings in SAGE Therapeutics by 108.0% in the first quarter. Bamco Inc. NY now owns 183,263 shares of the biopharmaceutical company’s stock valued at $29,518,000 after acquiring an additional 95,140 shares in the last quarter. Columbus Circle Investors raised its holdings in SAGE Therapeutics by 33.3% in the first quarter. Columbus Circle Investors now owns 28,285 shares of the biopharmaceutical company’s stock valued at $4,556,000 after acquiring an additional 7,063 shares in the last quarter. State of New Jersey Common Pension Fund D acquired a new stake in SAGE Therapeutics in the first quarter valued at approximately $805,000. Neuberger Berman Group LLC raised its holdings in SAGE Therapeutics by 15.3% in the first quarter. Neuberger Berman Group LLC now owns 3,459 shares of the biopharmaceutical company’s stock valued at $557,000 after acquiring an additional 459 shares in the last quarter. Finally, Fiduciary Trust Co. increased its stake in SAGE Therapeutics by 22.4% in the first quarter. Fiduciary Trust Co. now owns 23,400 shares of the biopharmaceutical company’s stock valued at $3,769,000 after purchasing an additional 4,289 shares during the last quarter. 95.31% of the stock is currently owned by hedge funds and other institutional investors.
In related news, Director Steven M. Paul sold 58,139 shares of SAGE Therapeutics stock in a transaction on Tuesday, March 6th. The shares were sold at an average price of $172.00, for a total value of $9,999,908.00. Following the transaction, the director now directly owns 632,712 shares in the company, valued at approximately $108,826,464. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Kimi Iguchi sold 28,153 shares of SAGE Therapeutics stock in a transaction on Wednesday, April 25th. The shares were sold at an average price of $142.73, for a total transaction of $4,018,277.69. Following the completion of the transaction, the chief financial officer now owns 63,499 shares in the company, valued at $9,063,212.27. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 164,427 shares of company stock worth $26,811,600. Insiders own 6.10% of the company’s stock.
SAGE Therapeutics (NASDAQ:SAGE) last announced its earnings results on Thursday, May 3rd. The biopharmaceutical company reported ($1.68) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.84) by $0.16. During the same quarter in the previous year, the business earned ($1.52) EPS. research analysts predict that SAGE Therapeutics Inc will post -8.26 EPS for the current year.
Several equities analysts have commented on the stock. Canaccord Genuity reiterated a “buy” rating and issued a $210.00 price target on shares of SAGE Therapeutics in a research note on Thursday, May 3rd. BidaskClub upgraded shares of SAGE Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday. ValuEngine upgraded shares of SAGE Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, May 2nd. Cowen reiterated a “buy” rating on shares of SAGE Therapeutics in a research note on Thursday, May 3rd. Finally, SunTrust Banks increased their price target on shares of SAGE Therapeutics to $203.00 and gave the company a “buy” rating in a research note on Wednesday, February 28th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $185.20.
SAGE Therapeutics Profile
Sage Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders. Its lead product candidate comprises brexanolone, a proprietary intravenous formulation of allopregnanolone that has completed III clinical trials for the treatment of post-partum depression (PPD).
Want to see what other hedge funds are holding SAGE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SAGE Therapeutics Inc (NASDAQ:SAGE).
Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.